Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age

Journal of Rheumatology

Volumn 39, Issue 6, 2012, Pages 1287-1290

  Bracaglia, Claudia ^a   Buonuomo, Paola S ^a   Tozzi, Alberto E ^a   Pardeo, Manuela ^a   Nicolai, Rebecca ^a   Campana, Andrea ^a   Insalaco, Antonella ^a   Cortis, Elisabetta ^a   De Benedetti, Fabrizio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Age under 4; Children; Etanercept; Juvenile idiopathic arthritis

Indexed keywords

AMIKACIN; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CEFTRIAXONE; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INTERLUEKIN 1 INHIBITOR; LINEZOLID; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ARTICLE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INCIDENCE; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; MALE; MALIGNANT NEOPLASTIC DISEASE; NECROTIZING FASCIITIS; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; OPPORTUNISTIC INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHICKENPOX; CHILD, PRESCHOOL; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; INFANT; JOINTS; MALE; METHOTREXATE; RANGE OF MOTION, ARTICULAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOVERY OF FUNCTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84861808072     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111555     Document Type: Article

References (15)

1. Petty R, Malleson P. Epidemiology of juvenile rheumatoid arthritis. World Pediatr Child Care 1987;3:205-10.
2. Cassidy JT, Petty RE, Laxer RM, editors. Textbook of pediatric rheumatology. 5th ed. Philadelphia: Elsevier; 2005.
3. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671-84. (Pubitemid 41407360)
4. Wallace CA. Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2006;20:279-300.
5. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, Oliveira S, Falcini F, et al, for the Pediatric Rheumatology INternational Trials Organization (PRINTO). A randomized trial of parenteral methotrexate comparing an intermediate with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50;2191-201. (Pubitemid 38924397)
6. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al; for the Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48:218-26. (Pubitemid 36091666)
7. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al; for the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94. (Pubitemid 43877949)
8. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al; for the Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504. (Pubitemid 351705939)
9. Tzaribachev N, Kuemmerle-Deschner J, Eichner M, Horneff G. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. Rheumatol Int 2008;28:1031-4.
10. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2. (Pubitemid 38160763)
11. US National Cancer Institute. National Institutes of Health. Cancer therapy evaluation program. Common terminology criteria for adverse events. Version 3.0. August 9, 2006. [Internet. Accessed March 23, 2012.] Available from: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf
12. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
13. Insalaco A, Bracaglia C, Cortis E, Campana A, Ugazio AG. Side effects of etanercept in a cohort of 76 children with rheumatic diseases. EULAR June 2006. Ann Rheum Dis 2006;65 Suppl II:246.
14. Horneff G, Schmeling H, Biedermann T. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44. (Pubitemid 39573695)
15. Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009;36:1078-82.